股票 › ETON
伊顿制药 ETON
美股市值排名 #2882
$56.46 +$9.31 (+19.75%)
休市 · Nov 6, 10:10 pm ET · 最新盘后价 $56.80 +0.60%
开盘$58.59
昨收$47.15
当日区间$51.82 – $58.59
成交量1.27M
市值$1.63B
市盈率（TTM）36.7
股息率–
ETON 相关新闻
匹配 Eton Pharmaceutical 或代码 ETON 的头条新闻，按最新排序。
- Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (Miltefosine) Capsules
- Eton Pharmaceutical(ETON.US) Officer Sells US$6.09 Million in Common Stock
- Upgrade: Analysts Just Made A Notable Increase To Their Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Forecasts 正面
- B. Riley Adjusts Price Target on Eton Pharmaceuticals to $70 From $40, Maintains Buy Rating
- H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $70 正面
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $76 正面
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $62
- H.C. Wainwright Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Raises Target Price to $65 正面
- 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
- CCORF Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $60
- Craig-Hallum Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $62
- 4/A: Eton Pharmaceutical | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-10% Owner Opaleye Management Inc.
- CCORF Initiates Eton Pharmaceutical(ETON.US) With Buy Rating, Announces Target Price $60
- 4: Eton Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner Opaleye Management Inc.
- B. Riley Securities Maintains Eton Pharmaceutical(ETON.US) With Buy Rating, Maintains Target Price $40
暂无评论——快来第一个聊聊 ETON。
登录后参与讨论。